Which drugs does patent 5,849,911 protect, and when does it expire?
Patent 5,849,911 protects REYATAZ and EVOTAZ and is included in three NDAs. There have been three Paragraph IV challenges on Reyataz.
Protection for REYATAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-six patent family members in twenty-nine countries.